Buy-and-Bill Pharma Contracting and Margin Risks

GPOs negotiate volume discounts on drug acquisition prices. That contract price is one of two numbers that set margin before reimbursement even enters the picture, and most practices treat the headline discount as the price they're actually paying. That assumption breaks down in four specific ways, and each one costs money quietly.

Tiered pricing is the first problem. Discount depth depends on hitting volume commitments, and a smaller or single-site practice may not clear those thresholds every month. When it doesn't, it pays more per unit than the contract's advertised rate suggests, and nobody on the finance side goes back to adjust the assumption.

Timing creates the second problem. GPO pricing gets set on its own schedule, while ASP recalculates every quarter. When ASP drops faster than the GPO contract cycle can keep up, the spread narrows quietly. Nobody flags it, because there's no single event that triggers a review.

Contract structure is the third wrinkle. Some GPO deals cover one drug; others bundle a whole portfolio. A bundled contract might deliver strong pricing on high-volume agents while leaving a niche biologic on much weaker terms, buried in the same agreement, unnoticed until someone runs the numbers drug by drug.

Then there's 340B, which carries real upside alongside a compliance layer that has to be watched closely. Practices that qualify get acquisition costs well below GPO rates on eligible drugs, but every 340B claim needs the JG modifier and every non-340B claim needs TB. Payers audit modifier accuracy now, so one wrong modifier on one claim turns into a reimbursement cut, a compliance finding, or both. All of it still depends on the drug getting purchased through the contracted channel in the first place, and that dependency is the opening white-bagging walks through.

How white-bagging mandates remove the acquisition margin entirely

White-bagging means the payer, not the practice, decides who dispenses the drug. A payer-designated specialty pharmacy fills the order and ships it straight to the practice for administration. The practice never buys the drug, so there's no acquisition margin to earn, and the spread that buy-and-bill depends on simply doesn't exist on that claim. This ranks among the biggest structural threats to infusion economics right now, right alongside any pricing quirk buried in a GPO contract.

Here's the part most practices get wrong about why it's spreading: major insurers own PBMs and specialty pharmacies outright now, so routing drug margin to a payer-owned pharmacy instead of an independent practice helps the insurer's own balance sheet directly. Cost containment gets cited as the rationale, and there's truth to it, but it's incomplete on its own, and treating the two as the same thing is exactly where practices misread the mandate.

The categories affected keep growing: oncology, rheumatology, rare disease, the therapeutic classes that anchor most infusion center revenue. Options for pushing back are narrow, and none of them scale well. A practice can appeal a mandate on clinical grounds, drug stability or patient safety, and that works for some agents but not most. Hospital-affiliated infusion centers can clear-bag through their own specialty pharmacy, a path closed to independent practices without that infrastructure. For most independent centers, the realistic move is accepting the reduced reimbursement and rebuilding the cost model around a mandate that isn't going away.

Some states have passed laws addressing white-bagging as of 2025, and that protection is real where it exists. But it's uneven state to state, and federal preemption questions for ERISA plans remain unsettled. Meanwhile payers pull a second lever at the same time: steering patients toward lower-cost sites of care, which cuts infusion center volume regardless of what happens with drug pricing at all.

ASP dynamics and sequestration as recurring, silent margin drains

ASP resets every quarter based on manufacturer-reported sales data. Any practice reimbursed on an ASP-linked rate is exposed to a downward revision every 90 days, whether or not its own acquisition cost moved at all.

Here's the part that catches practices off guard: when a manufacturer gives a bigger rebate to some other buyer, a hospital system, a large distributor, that concession flows into the ASP calculation and drags the whole reimbursement benchmark down with it. The infusion center absorbs the fallout of a deal it had no part in and never saw the terms of.

Sequestration stacks right on top of that. It applies a mandatory cut to Medicare payments, pushing the realized rate below the statutory ASP-plus-percentage ceiling on every Medicare claim, with zero adjustment for what the practice actually paid to acquire the drug.

The slower trap is renegotiation, or the lack of it. A practice that locked in payer contract terms back when ASP sat higher, and hasn't gone back to the table since, is probably running on a margin assumption that no longer matches reality. The contract reads fine on paper even as the spread it was built on quietly shrinks underneath it. Commercial payers add one more layer here: negotiated rate floors that cap reimbursement below what the ASP math would otherwise produce, often buried in language that never surfaces as a clear, drug-specific rate schedule anyone actually checks.

J-code billing accuracy as a direct margin variable, not a back-office compliance task

A buy-and-bill claim needs the right J-code, the right NDC, the right unit count, and the right administration code, all matching each other, or the claim goes into automatic denial or bundling, no human review required.

Units carry the most risk. J-code descriptors specify an exact metric, per 10 mg, per 1 mg, and the administered dose has to translate into the correct billed units. Undercode, and the practice eats a systematic underpayment on every claim using that code. Overcode, and now it's sitting on overpayment liability and a future audit. Neither error announces itself; both just repeat, quietly, claim after claim.

Multi-drug encounters, common in oncology and rheumatology infusion, bring their own hazard: infusion hierarchy errors. Get the hierarchy wrong and NCCI edits kick in, triggering automatic bundling or an outright denial. This ranks among the most common mistakes in infusion billing, and it's largely preventable with the right claim scrubbing before submission.

Weight-based dosing adds another layer the claim has to survive. A custom dose calculated from a patient's weight has to move from the clinical chart to the billed units without a rounding error creeping in, and one small rounding slip on one encounter becomes a recurring, quiet underpayment across every encounter that follows the same pattern.

And the 340B modifier issue from earlier shows back up here, at the claim level: a JG versus TB mismatch is a live financial risk right now, generating both reimbursement cuts and compliance findings as payers ramp up 340B audits. Run the math across high-dollar biologics like bevacizumab, rituximab, or pembrolizumab, and even a small per-claim error rate adds up to real revenue loss at scale.

How underpayments hide inside paid claims and become permanent write-offs

An underpayment isn't a denial. The claim went through, a payment landed, and that's exactly why it slips past denial management workflows built to catch rejected claims, not shortchanged ones.

The mechanism is simple, and that's what makes it dangerous. The payer adjudicates below the contracted rate, the shortfall shows up as an adjustment line on the ERA, and the claim closes out as "paid" in most patient accounting systems. Nobody flags the gap between what the contract says and what actually landed in the bank, because the system sees a paid claim and moves to the next one.

Providers lose a meaningful share of net revenue to commercial underpayments every year, and for infusion-heavy practices the exposure runs higher still. The dollar values per claim are large enough that even a small percentage gap turns into a large number fast. In buy-and-bill specifically, if the adjudicated rate doesn't cover acquisition cost plus the expected spread, the practice just financed part of the payer's drug cost, and it may never find out without checking the remittance line by line.

Fixing this takes a workflow built around reconciliation, alongside denial review rather than folded into it. Load the contracted rate into the system, match it against the ERA at the line level, and flag exceptions before the claim ages past the point of recovery. Once a claim slips past its contract's timely appeal window, the underpayment stops being a recoverable gap and becomes a permanent write-off, and no amount of follow-up changes that.

Prior authorization as a margin risk that starts before the drug is purchased

By the time a buy-and-bill claim gets submitted, the drug has already been bought and given to the patient. A PA denial at that point doesn't stop the cost from happening; it just leaves that cost with nowhere to go. Most revenue cycle conversations treat PA as a front-desk task, and that framing undersells what's actually at stake. PA is the one point in the entire buy-and-bill sequence where margin risk is still preventable, rather than already locked in, and treating it as clerical is how practices lose the one chance they had to stop the bleeding before it starts.

Manual prior authorization runs roughly $93,000 per physician per year, according to the CAQH 2024 Index, and that figure doesn't count the revenue lost when a denial goes unappealed or an authorization lapses between treatment cycles. Overall PA volume has climbed steadily, and denial rates have climbed right alongside it, so the administrative burden and the financial exposure compound together instead of offsetting each other.

Recurring infusion therapies bring a specific trap: authorization renewal windows that vary by payer and by drug. Miss the gap between when the old auth expires and the new one needs to be in place, and the result is a denial on a drug that's already sitting in the patient's bloodstream, with no way to undo it after the fact.

Here's the part worth sitting with: among PA denials that actually get appealed, most get overturned, fully or partially. That result argues for staffing an active appeals process instead of writing denials off as a cost of doing business. The workflow that protects margin has a clear shape. Verify benefits and PA requirements before scheduling. Submit a complete clinical package at initiation, diagnosis, treatment history, labs, and rationale together, not in pieces. Track submission status actively, since a request the payer never received is a common and preventable failure point. Trigger renewal before expiration, not after a lapse forces the issue, and staff peer-to-peer appeals to run within a set window instead of sitting in a queue indefinitely.

Where to locate margin risk before it becomes margin loss

Buy-and-bill margin takes hits from several directions at once: acquisition cost, reimbursement benchmarks, payer rate floors, billing execution, and authorization management. No single fix covers all of it, and any practice hunting for the one lever to pull is going to be disappointed.

Real control starts at scheduling, well before a claim ever gets submitted. Most recoverable problems, wrong benefits information, missing authorization, a drug purchased against an approval that already expired, get seeded at that first step, long before anyone touches a claim form. Fixing intake keeps half the downstream losses from ever happening in the first place, and that's the highest-leverage fix in this entire piece, the one most practices skip because it doesn't look like a billing problem yet.

Payer contracts need standing review, not a one-time signature and a filing cabinet. Rate floors negotiated back when ASP sat higher may no longer cover today's acquisition cost plus a workable spread, and renegotiating that gap requires knowing it's there first.

Denial analysis has to get specific: specific to the payer, specific to the root cause. Lumping denials into one generic bucket buries the signal. A pattern of PA mismatches at one payer calls for a completely different fix than a timely-filing breakdown on secondary claims at another; treating them the same wastes the data both problems are trying to hand over.

Underpayment recovery needs its own workflow too, separate from denial management, built around line-level ERA reconciliation, a loaded contract rate to check against, and exceptions worked before the recovery window shuts.

General-purpose revenue cycle platforms weren't built for what buy-and-bill actually demands: J-code complexity, 340B modifier discipline, PA lifecycle tracking, and line-level remittance reconciliation, all running at once. Practices leaning on generic tools for this job are more likely to absorb the losses described above than to catch them, and if staff are still hand-checking ERAs line by line and chasing PA renewal dates on a spreadsheet, that's a sign the system underneath them already failed. Some practices have moved toward infusion-specific billing and AR platforms, like Ruby RCM, a revenue cycle management platform built specifically for infusion centers and buy-and-bill practices that pairs software with hands-on operators to handle the full workflow from prior authorization through denial management and payment reconciliation.